Loading...
MIRO logo

Miromatrix Medical Inc.NasdaqCM:MIRO Stock Report

Market Cap US$93.0m
Share Price
n/a
1Y18.5%
7D1.2%
1D0.6%
Portfolio Value
​
View

Miromatrix Medical Inc.

NasdaqCM:MIRO Stock Report

Market Cap: US$93.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Miromatrix Medical (MIRO) Stock Overview

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. More details

MIRO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Revenue is forecast to grow 77.68% per year

Risk Analysis

Makes less than USD$1m in revenue ($958K)

Highly volatile share price over the past 3 months

Has less than 1 year of cash runway

Does not have a meaningful market cap ($93M)

+ 2 more risks

MIRO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW489,733 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
489,733 investors already sharing narratives
View all narratives

Miromatrix Medical Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Miromatrix Medical
Historical stock prices
Current Share PriceUS$3.39
52 Week HighUS$3.73
52 Week LowUS$0.91
Beta0.015
1 Month Change1.50%
3 Month Change149.26%
1 Year Change18.53%
3 Year Changen/a
5 Year Changen/a
Change since IPO-77.76%

Recent News & Updates

Analysis Article • Oct 28

Miromatrix Medical (NASDAQ:MIRO) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

Analysis Article • Oct 28

Miromatrix Medical (NASDAQ:MIRO) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 01

We're A Little Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 08

Here's Why We're A Bit Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Sep 30

Here's Why We're Watching Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 25

Miromatrix gets US patent for recellularizing technology for use in organ transplant

Miromatrix Medical (NASDAQ:MIRO) said it has received a new patent from the U.S. Patent and Trademark Office for its perfusion decellularization and recellularization technology. The patent number 11,414,644 titled 'Methods of Recellularizing a Tissue or Organ for Improved Transplantability' covers the revascularization of decellularized organs and tissues which include all types of organs including liver, lung, kidney, and heart. The new patent expands the company's patent portfolio covering the bioengineering of transplantable organs, Miromatrix said in an Aug. 25 press release.
Seeking Alpha • Aug 15

Miromatrix Medical GAAP EPS of -$0.40 misses by $0.07, revenue of $3.95M

Miromatrix Medical press release (NASDAQ:MIRO): Q2 GAAP EPS of -$0.40 misses by $0.07. Revenue of $3.95M.

Shareholder Returns

MIROUS Life SciencesUS Market
7D1.2%0.3%0.7%
1Y18.5%16.3%20.6%

Return vs Industry: MIRO exceeded the US Life Sciences industry which returned -8.9% over the past year.

Return vs Market: MIRO exceeded the US Market which returned 17.1% over the past year.

Price Volatility

Is MIRO's price volatile compared to industry and market?
MIRO volatility
MIRO Average Weekly Movement61.8%
Life Sciences Industry Average Movement9.1%
Market Average Movement7.3%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: MIRO's share price has been volatile over the past 3 months.

Volatility Over Time: MIRO's weekly volatility has increased from 33% to 62% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200976Jeff Rosswww.miromatrix.com

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company’s proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute.

Miromatrix Medical Inc. Fundamentals Summary

How do Miromatrix Medical's earnings and revenue compare to its market cap?
MIRO fundamental statistics
Market capUS$92.95m
Earnings (TTM)-US$27.41m
Revenue (TTM)US$958.03k
97.0x
P/S Ratio
-3.4x
P/E Ratio

Is MIRO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MIRO income statement (TTM)
RevenueUS$958.03k
Cost of RevenueUS$500.00k
Gross ProfitUS$458.03k
Other ExpensesUS$27.87m
Earnings-US$27.41m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.00
Gross Margin47.81%
Net Profit Margin-2,861.11%
Debt/Equity Ratio2.5%

How did MIRO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/14 00:07
End of Day Share Price 2023/12/12 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Miromatrix Medical Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander NowakCraig-Hallum Capital Group LLC
Matthew O'BrienPiper Sandler Companies